Inotec AMD, whose product NATROX® O₂ is the leader in continuous topical oxygen therapy (cTOT) for advanced wound care, today announced the successful close of a $33 million Series C financing round. The funding, led by existing investors, Amadeus Capital Partners, Meltwind, Puhua Capital and the Wealth Club, marks a major milestone in the company’s mission to heal every chronic wound and improve patients’ lives on a global scale.
The proceeds from this round will be strategically used to secure national reimbursement in the United States for the company’s advanced therapy, NATROX O₂, ensuring broader accessibility for patients across the US. Additionally, the funds will support the expansion of the company’s leadership team, strengthening its global capabilities to drive future growth and innovation.
Leading the Way in Topical Oxygen Therapy with NATROX O₂
Founded with a commitment to address critical gaps in wound care, Inotec AMD has focused on developing advanced topical oxygen therapy solutions that enhance healing and improve patients’ quality of life. The company’s flagship cTOT product, NATROX O₂, delivers a continuous flow of oxygen directly to the wound, creating an optimal environment for healing. NATROX O₂ has set new standards in wound care, providing a non-invasive, wearable solution that is accessible for both patients and healthcare providers.
“Inotec AMD’s global success is rooted in our dedication to patient-centric innovation, especially through our work with NATROX O₂,” said Craig Kennedy, CEO of Inotec AMD. “This latest round of financing underscores the confidence our investors have in our vision and our ability to make a significant impact in the wound care space providing life-altering improvements for our patients.”
Positioned for Future Growth
With the new capital, Inotec AMD is poised to accelerate its strategic initiatives, including the essential step of obtaining national US reimbursement for NATROX O₂. This achievement will pave the way for greater adoption of its cTOT technology, enabling healthcare providers to offer a simple, user-friendly therapy designed to accelerate healing, even in wounds that have persisted for years, such as diabetic foot ulcers, venous leg ulcers, pressure injuries, and non-healing surgical or traumatic wounds.
More than 100 million people in the world suffer from wounds that will not heal. In the US, wound care costs the health services an estimated $97 billion annually, with chronic wounds making up $50 billion of that expense. In the UK, the NHS spends as much on wound care as it does on oncology, mostly because chronic wounds can’t be healed reliably — until now.
Pierre Socha, Partner, Amadeus Capital Partners: “Amadeus backed Natrox from inception and it is fulfilling to see this best-in-class technology now available in a growing number of markets. NATROX O₂ is already authorized to sell in 46 countries. It is becoming the reference advance therapy for the healing of chronic wounds across private and public health systems globally. Securing national coverage in the US is another step forward for the team.”